Mizuho Maintains Outperform on Kymera Therapeutics, Raises Price Target to $140
Benzinga Newsdesk 3 months ago
Analyst RatingsNewsPrice Target
Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.
Mizuho analyst Joseph Catanzaro maintains Kymera Therapeutics (NASDAQ:KYMR) with a Outperform and raises the price target from $120 to $140.